AdFalciVax – ICMR Malaria Vaccine (2025 EoI)
Exam Level: UPSC / Science & Technology | Content Type: Notes + MCQs
🧬 1️⃣ Overview
The Indian Council of Medical Research (ICMR), New Delhi has invited Expressions of Interest (EoI) for technology transfer and commercialization of AdFalciVax, a recombinant chimeric multi-stage malaria vaccine.
🦟 Target Pathogen: Plasmodium falciparum
📅 EoI Released: July 17, 2025
⏳ Deadline: August 17, 2025
🏥 2️⃣ Development & Validation
| Institution | Role |
|---|---|
| ICMR-RMRC Bhubaneswar | Lead Developer |
| ICMR-NIMR | Preclinical Validation |
| NII Delhi | Scientific Validation Support |
🎯 Objective: Prevent human infection and reduce community-level malaria transmission.
📑 3️⃣ Technology Transfer & Licensing
- Selected companies receive licensing rights for development, manufacturing & commercialization.
- Technical support provided by RMRC & ICMR.
- Submission via the Medical Innovation Patent Mitra Portal.
🌍 4️⃣ Significance
- Targets the most severe malaria-causing parasite.
- Strengthens India’s indigenous vaccine development ecosystem.
- Supports public health and malaria elimination goals.
📝 5️⃣ Multiple-Choice Questions (MCQs)
Question 1:
Which organization issued the EoI?
A) DBT
B) ICMR
C) WHO
D) UNICEF
Answer: B
Explanation: ICMR invited expressions of interest for AdFalciVax commercialization.
Which organization issued the EoI?
A) DBT
B) ICMR
C) WHO
D) UNICEF
Answer: B
Explanation: ICMR invited expressions of interest for AdFalciVax commercialization.
Question 2:
AdFalciVax targets:
A) Plasmodium vivax
B) SARS-CoV-2
C) Plasmodium falciparum
D) Dengue virus
Answer: C
Explanation: It is designed against Plasmodium falciparum.
AdFalciVax targets:
A) Plasmodium vivax
B) SARS-CoV-2
C) Plasmodium falciparum
D) Dengue virus
Answer: C
Explanation: It is designed against Plasmodium falciparum.
Question 3:
Lead developer institute:
A) ICMR-NIMR
B) ICMR-RMRC Bhubaneswar
C) NII Delhi
D) AIIMS Delhi
Answer: B
Explanation: RMRC Bhubaneswar developed the vaccine.
Lead developer institute:
A) ICMR-NIMR
B) ICMR-RMRC Bhubaneswar
C) NII Delhi
D) AIIMS Delhi
Answer: B
Explanation: RMRC Bhubaneswar developed the vaccine.
Question 4:
EoI submission deadline:
A) Sept 1, 2025
B) August 17, 2025
C) July 31, 2025
D) Oct 1, 2025
Answer: B
Explanation: Deadline is August 17, 2025.
EoI submission deadline:
A) Sept 1, 2025
B) August 17, 2025
C) July 31, 2025
D) Oct 1, 2025
Answer: B
Explanation: Deadline is August 17, 2025.
Question 5:
Portal for EoI submission:
A) IndiaBiospace
B) Patent Mitra Portal
C) Arogya Setu
D) GAVI Portal
Answer: B
Explanation: Applications must be submitted via the Medical Innovation Patent Mitra portal.
Portal for EoI submission:
A) IndiaBiospace
B) Patent Mitra Portal
C) Arogya Setu
D) GAVI Portal
Answer: B
Explanation: Applications must be submitted via the Medical Innovation Patent Mitra portal.
